drugset / Trial / NCT00674557

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

NCT00674557

Phase 2 Terminated 111 enrolled Cancer Research UK
RandomizedOpen-labelTreatment

Summary

RATIONALE: Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ATN-224 may stop the growth of breast cancer by blocking blood flow to the tumor. It is not yet known whether giving exemestane together with ATN-224 is more effective than giving exemestane alone in treating patients with recurrent or advanced breast cancer. PURPOSE: This randomized phase II trial is studying the side effects of exemestane given together with or without ATN-224 and to see how well it works in treating postmenopausal women with recurrent or advanced breast cancer.

Timeline

Start
2008-06
Primary completion
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Exemestane Small molecule Oral
Subject TIOMOLIBDATE CHOLINE Small molecule

Indications